Acurx Pharmaceuticals (ACXP) Stock Price, News & Analysis

Company Overview

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

Key Stats

• Today's Range: $4.17 to $4.68
• 50-Day Range: $4.47 to $16.41
• 52-Week Range: $4.17 to $47.80
• Volume: 58,498 shs
• Average Volume: 50,482 shs
• Market Capitalization: $6.88 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $160.00
• Consensus Rating: Buy

Acurx Pharmaceuticals Stock Analysis - MarketRank™

Acurx Pharmaceuticals scored higher than 42% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Acurx Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Acurx Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Acurx Pharmaceuticals are expected to decrease in the coming year, from ($0.89) to ($2.06) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Acurx Pharmaceuticals is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Acurx Pharmaceuticals is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Acurx Pharmaceuticals has a P/B Ratio of 7.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.48% of the float of Acurx Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Acurx Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Acurx Pharmaceuticals has recently decreased by 2.95%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Acurx Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Acurx Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.48% of the float of Acurx Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Acurx Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Acurx Pharmaceuticals has recently decreased by 2.95%, indicating that investor sentiment is improving.

News and Social Media

• Score: 0.7 / 5
• News Sentiment: -0.67

News Sentiment

Acurx Pharmaceuticals has a news sentiment score of -0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Acurx Pharmaceuticals this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for ACXP on MarketBeat in the last 30 days. This is a decrease of -89% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Acurx Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Acurx Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

26.00% of the stock of Acurx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 11.53% of the stock of Acurx Pharmaceuticals is held by institutions.

ACXP Stock Analysis - Frequently Asked Questions

How have ACXP shares performed this year?

Acurx Pharmaceuticals' stock was trading at $16.28 at the start of the year. Since then, ACXP shares have decreased by 72.5% and is now trading at $4.47.

How were Acurx Pharmaceuticals' earnings last quarter?

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) issued its earnings results on Monday, May, 12th. The company reported ($2.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.80) by $0.60.
Read the conference call transcript.

When did Acurx Pharmaceuticals' stock split?

Shares of Acurx Pharmaceuticals reverse split on the morning of Tuesday, August 5th 2025.A 1-20 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 4th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

When did Acurx Pharmaceuticals IPO?

Acurx Pharmaceuticals (ACXP) raised $15 million in an initial public offering (IPO) on Friday, June 25th 2021. The company issued 2,500,000 shares at a price of $5.00-$7.00 per share. Alexander Capital, L.P. and Network 1 Financial Securities acted as the underwriters for the IPO.

Who are Acurx Pharmaceuticals' major shareholders?

Acurx Pharmaceuticals' top institutional shareholders include Prospect Financial Services LLC (19.30%), Geode Capital Management LLC (9.52%) and O Brien Greene & Co. Inc (0.20%). Insiders that own company stock include David P Luci and Joseph C Scodari.
View institutional ownership trends.

How do I buy shares of Acurx Pharmaceuticals?

Shares of ACXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Acurx Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Acurx Pharmaceuticals investors own include Avino Silver & Gold Mines (ASM), PayPal (PYPL), Adverum Biotechnologies (ADVM), Rolls-Royce Holdings PLC (RYCEY), Shopify (SHOP), AbCellera Biologics (ABCL) and atai Life Sciences (ATAI).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 8/08/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ACXP
• CIK: 1736243
• Web: www.acurxpharma.com
• Phone: 917-533-1469
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Acurx Pharmaceuticals: $160.00
• High Price Target: $160.00
• Low Price Target: $160.00
• Potential Upside/Downside: +3,479.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($14.00)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$14.10 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -526.78%
• Return on Assets: -223.78%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.93
• Quick Ratio: 1.93

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.63 per share
• Price / Book: 7.10

Miscellaneous

• Outstanding Shares: 1,540,000
• Free Float: 1,138,000
• Market Cap: $6.88 million
• Optionable: Optionable
• Beta: -1.27